Authors: Yosef Laviv Steven Jackson Zvi Harry Rappaport
Publish Date: 2014/12/19
Volume: 157, Issue: 2, Pages: 241-245
Abstract
Subependymal giant cell tumor SGCT is a benign intraventricular tumor usually located near the foramen of Monro It is almost always associated with tuberous sclerosis complex TSC SGCTs may obstruct cerebrospinal fluid CSF pathways Rarely they may secrete a proteinrich exudate causing communicating hydrocephalus Surgery is indicated for symptomatic lesions or growing asymptomatic lesions The operative approach to SGCT has shifted from simple shunt placement to a more aggressive approach leading to early attempts at gross total resection Recently the mTOR inhibitor everolimus has been approved for treating SGCT In this article we present two cases of recurrent shunt malfunctions in adult TSC patients with proteinsecreting SGCTs We describe the complexity of treating such patients with an emphasis on the role mTOR inhibitors may have in their management We also review the literature on surgical management of SGCTrelated hydrocephalusAll authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest such as honoraria educational grants participation in speakers’ bureaus membership employment consultancies stock ownership or other equity interest and expert testimony or patentlicensing arrangements or nonfinancial interest such as personal or professional relationships affiliations knowledge or beliefs in the subject matter or materials discussed in this manuscript
Keywords: